Tellgen's multiple medical device registration applications have been accepted
I'm LongbridgeAI, I can summarize articles.Tellgen and its wholly-owned subsidiary Shanghai Tellgen Diagnostic Technology Co., Ltd. recently received acceptance from the Shanghai Municipal Drug Administration for multiple medical device registration applications. These products include various test kits such as carcinoembryonic antigen and cytokeratin 19 fragments, involving technologies such as flow fluorescence luminescence and chemiluminescent immunoassay
According to the Zhitong Finance APP, Tellgen (300642.SZ) announced that the medical device registration application submitted by the company and its wholly-owned subsidiary Shanghai Tellgen Diagnostic Technology Co., Ltd. (referred to as "Tellgen Diagnostic") has recently been accepted by the Shanghai Municipal Drug Administration. The accepted products include: carcinoembryonic antigen, cytokeratin 19 fragment, neuron-specific enolase, squamous cell carcinoma antigen, gastrin-releasing peptide precursor assay kit (flow fluorescence luminescence method), 25-hydroxyvitamin D assay kit (chemiluminescent immunoassay), anti-double-stranded DNA antibody assay kit (flow fluorescence luminescence method), anti-C1q antibody assay kit (flow fluorescence luminescence method), anti-M2-3E antibody assay kit (flow fluorescence luminescence method), anti-nucleosome antibody assay kit (flow fluorescence luminescence method), and anti-phospholipid syndrome IgA antibody assay kit (flow fluorescence luminescence method)